MFG
VNDA icon

Magnus Financial Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Magnus Financial Group’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-9,664
Closed -$253K – 543
2018
Q4 		$253K Buy
+9,664
New +$227K 0.07% 254

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Magnus Financial Group's VNDA Position: Q1 2019 in Review

Magnus Financial Group sold out of Vanda Pharmaceuticals (VNDA) in Q1 2019, closing a stake of 9,664 shares — an estimated $253K sold.

Magnus Financial Group first reported a position in VNDA in Q4 2018 and held it in 1 quarter. The position peaked at $253K in Q4 2018. 179 funds tracked by Wall St. Rank hold VNDA as of Q1 2019.

  • Magnus Financial Group reported no remaining Vanda Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Magnus Financial Group sold 9,664 Vanda Pharmaceuticals shares in Q1 2019, an estimated $253K.
  • Magnus Financial Group first reported a position in Vanda Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Magnus Financial Group's Vanda Pharmaceuticals position peaked at $253K in Q4 2018.
  • 179 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2019.

Based on Magnus Financial Group's 13F filing for Q1 2019, filed 9 May 2019.